What is the price target for ANTX stock?
6 analysts have analysed ANTX and the average price target is 1.02 USD. This implies a price decrease of -79.35% is expected in the next year compared to the current price of 4.94.
AN2 THERAPEUTICS INC (ANTX) Forecast, Price Target & Analyst Ratings
NASDAQ:ANTX • US0373261058
Current stock price
4.94 USD
-0.5 (-9.19%)
At close:
4.91 USD
-0.03 (-0.61%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AN2 THERAPEUTICS INC (ANTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.24
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.02
Upside
-79.35%
From current price of $4.94 to mean target of $1.02, Based on 6 analyst forecasts
Low
$1.01
Median
$1.02
High
$1.05
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for ANTX. The average price target is 1.02 USD. This implies a price decrease of -79.35% is expected in the next year compared to the current price of 4.94.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
ANTX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ANTX.
In the previous month the buy percentage consensus was at a similar level.
ANTX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-05 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-03-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-03 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-18 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-08-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-05-16 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-04-02 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2024-04-01 | Oppenheimer | Reiterate | Perform -> Perform |
| 2024-02-13 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-02-12 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-02-12 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-02-12 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-01-04 | JMP Securities | Initiate | Market Outperform |
| 2023-03-30 | Oppenheimer | Maintains | Outperform |
| 2022-11-14 | SVB Leerink | Maintains | Outperform |
| 2022-04-19 | Oppenheimer | Initiate | Outperform |
| 2022-04-19 | Cowen & Co. | Initiate | Outperform |
| 2022-04-19 | Evercore ISI Group | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.24
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 2.08%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
ANTX is expected to report earnings on 4/1/2026. The consensus EPS estimate for the next earnings is -0.24 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -5.18M | -7.28M -40.54% | -21.57M -196.29% | -42.26M -95.92% | -69.635M -64.78% | -54.554M 21.66% | N/A 31.94% | N/A 21.43% | N/A 12.59% | N/A -76.40% | N/A 8.16% | N/A -7.65% | N/A -7.57% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -4.71 | -2.82 40.13% | -1.64 41.84% | N/A 30.34% | N/A 18.75% | N/A 12.09% | N/A -57.50% | N/A -7.94% | N/A -7.35% | N/A -7.53% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 2.08% | -0.23 32.97% | -0.23 -11.71% | -0.22 27.61% | -0.22 8.33% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.752M 9.97% | -7.548M 34.58% | -7.344M -1.77% | -7.242M 27.87% | -7.038M 9.21% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.53%
EPS Next 5 Year
2.91%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AN2 THERAPEUTICS INC / ANTX Forecast FAQ
What is the next earnings date for ANTX stock?
AN2 THERAPEUTICS INC (ANTX) will report earnings on 2026-04-01, after the market close.
What are the consensus estimates for AN2 THERAPEUTICS INC (ANTX) next earnings?
The consensus EPS estimate for the next earnings of AN2 THERAPEUTICS INC (ANTX) is -0.24 USD and the consensus revenue estimate is 0 USD.
How do analysts rate AN2 THERAPEUTICS INC (ANTX)?
The consensus rating for AN2 THERAPEUTICS INC (ANTX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.